Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine

International Journal of Urology

Volumn 14, Issue 12, 2007, Pages 1103-1106

  Kato, Toshiki ^a   Hashimoto, Yoshihiro ^a   Okada, Shinsuke ^a   Tozawa, Keiichi ^a   Takahashi, Satoru ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

CA19 9; Gemcitabine; Prostatic carcinoma; Prostatic ductal adenocarcinoma; Prostatic neoplasm

Indexed keywords

CA 19-9 ANTIGEN; CISPLATIN; GEMCITABINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DUCT ADENOCARCINOMA; RADICAL RETROPUBIC PROSTATECTOMY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CA-19-9 ANTIGEN; CISPLATIN; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 36349036507     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01908.x     Document Type: Article

References (10)

1. Melicow MM, Pachter MR. Endometrial carcinoma of prostate utricle (uterus masculinus). Cancer 1967 20 : 1715 22.
2. Christensen WN, Steinberg G, Walsh PC, Epstein JI. Prostatic duct Adenocarcinoma: Findings at radical prostatectomy. Cancer 1991 67 : 2118 24.
3. Epstein JI, Woodruff J. Prostatic carcinomas with endometrioid features: A light microscopic and immunohistochemical study of ten cases. Cancer 1986 57 : 111 19.
4. Epstein JI. Subtypes of prostate adenocarcinoma. In : Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (ed. Campbell-Walsh Urology, 9th edn. Saunderes Company, Philadelphia, PA, 2007 2880 1.
5. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? Am. J. Surg. Pathol. 1999 23 : 781 5.
6. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 1995 22 : 72 9.
7. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res. 1996 2 : 521 30.
8. Heinemann V, Quietzsch D, Gieseler F et al. Randomized Phase 3 trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 2006 24 : 3949 52.
9. Heinemann V, Schermuly MM, Stieber P et al. CA19-9: A predictor response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res. 1999 19 : 2433 6.
10. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: The implication for clinical trials. Br. J. Cancer 2005 93 : 740 3.